Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019

References

1. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in EU/EEA Member States. Stockholm: ECDC. [Accessed 8 Feb 2019]. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Seasonal-influenza-antiviral-use-EU-EEA-Member-States-December-2018_0.pdf
2. Department of Health/National Health Service (DoH/NHS). The flu immunisation programme 2013/14 – extension to children. London: DoH/NHS; 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225360/Children_s_flu_letter_2013.pdf
3. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. Geneva: WHO; 2018. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/201802_recommendation.pdf?ua=1
4. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe. (WHO/Europe). Flu News Europe. Summary week 3/2019 (14-20 January 2019). Stockholm: ECDC; 2019. Available from: https://flunewseurope.org/Archives
5. European Union (EU). EpiConcept. I-MOVE+ - Protocol for hospital-based test negative case control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Brussels: EU. [Accessed 2 May 2017]. Available from: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZXBpY29uY2VwdC5mcnxpbW92ZXBsdXN8Z3g6Njg0NjQwM2QxZDRlM2JmMw
6. European Union (EU). Generic protocol for the test negative design case control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. Brussels: EU; 2015. Available from: https://drive.google.com/file/d/0Byv9pYYPpY4PM25qSXczQ3g4T0E/view
7. Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Spanish Influenza Sentinel Surveillance System. Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data. Euro Surveill. 2015;20(28):21187.  https://doi.org/10.2807/1560-7917.ES2015.20.28.21187  PMID: 26212144 
8. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016;21(38):30348.  https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348  PMID: 27684603 
9. Emborg HD, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, et al. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 - a rapid epidemiological and virological assessment. Euro Surveill. 2016;21(14):30189.  https://doi.org/10.2807/1560-7917.ES.2016.21.14.30189  PMID: 27101732 
10. Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;35(36):4796-800.
11. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503-10.  https://doi.org/10.1016/0895-4356(95)00048-8  PMID: 8543964 
12. Covenay J. FIRTHLOGIT: Stata module to calculate bias reduction in logistic regression. Boston College Department of Economics; 2015.
13. Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill. 2019;24(4):1900055.  https://doi.org/10.2807/1560-7917.ES.2019.24.4.1900055  PMID: 30696523 
14. Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, et al. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019;68(6):135-9.  https://doi.org/10.15585/mmwr.mm6806a2  PMID: 30763298 
15. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe. (WHO/Europe). Flu News Europe. Virus characteristics week 6/2019 (4-10 February 2019). Stockholm: ECDC; 2019. Available from: https://flunewseurope.org/VirusCharacteristics
16. Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. PNAS. 2017;114(47):12578-12583.
17. Public Health England/Department of Health/National Health Service (PHE/DoH/NHS). Vaccines for 2019/20 seasonal flu vaccination programme. London: PHE/DoH/NHS; 2018. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/757784/Vaccines_for_2019_20_seasonal_flu_vaccination_programme.pdf
18. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in Europe. Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013-14 and 2014-15 influenza seasons. VENICE technical report. Stockholm: ECDC; 2016. Available from: http://venice.cineca.org/Seasonal-influenza-vaccination-antiviral-use-europe.pdf
19. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. Geneva: WHO; 2019. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/201902_recommendation.pdf?ua=1